search
atopic dermatitis
Trends
- 1Johns Hopkins Experts Offered to Discuss Eczema●Tip Sheet: Johns Hopkins Medicine Experts Available to Discuss Eczema (Atopic Dermatitis)
Johns Hopkins Medicine has announced that its experts are available to comment on eczema, also known as atopic dermatitis, a common chronic inflammatory skin condition. The announcement is aimed at journalists seeking medical sources, suggesting renewed media interest in eczema treatments, triggers and research developments.
- 2Johns Hopkins Experts Offer Comment on Eczema▼Tip Sheet: Johns Hopkins Medicine Experts Available to Discuss Eczema (Atopic Dermatitis) | Newswise
Johns Hopkins Medicine has made its eczema specialists available to journalists for interviews about atopic dermatitis, a common inflammatory skin condition affecting millions worldwide. The announcement, distributed via Newswise, comes as interest grows in new treatment options and management strategies for the condition, which can significantly affect quality of life for both children and adults.
- 3New Rezpegaldesleukin Data Shows Durable Results at EADV 2026▼New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026
New clinical data for rezpegaldesleukin, an immune-regulating drug candidate, show long-term durability and disease improvement in patients with alopecia areata and atopic dermatitis. The findings are being presented at the EADV Congress 2026, Europe's major dermatology meeting. The data support the treatment's potential for these chronic inflammatory skin conditions, where maintaining improvement over time remains a key challenge for patients and physicians.
- 4Age Shapes Dupilumab's Quality-of-Life Benefits in Children●Age Affects Dupilumab’s Quality-of-Life Benefits in Kids
New reporting indicates that dupilumab's benefits for quality of life in children vary depending on the child's age. The finding, highlighted by Medscape, suggests younger and older children may respond differently to the biologic drug, which is used for conditions such as atopic dermatitis and asthma. Clinicians may need to weigh age when considering treatment expectations.
- 5New Biomarker Data on Rezpegaldesleukin Presented at EADV Congress 2026●New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
New biomarker data on rezpegaldesleukin were presented in a late-breaking oral presentation at the EADV Congress 2026. The findings show early molecular responses to the drug across multiple immune pathways that are dysregulated in patients with atopic dermatitis. The data suggest the therapy, an immune-regulating treatment, is being positioned as a potential option for the inflammatory skin condition, and the presentation is drawing attention from the dermatology community.